Please login to the form below

Not currently logged in
Email:
Password:

Eisai moves to end Aricept partnership

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth. A tug of war is likely to ensue with Pfizer already denying that the Japanese drugmaker has any basis for this challenge.

The bone of contention and trigger for Eisai's claim appears to be Wyeth's in-pipeline Alzheimer's medications. When Pfizer announced its $68bn Wyeth buyout, it made an offhand reference to potential trouble with Eisai. This is the first real indication that the Japanese company wants out of the deal.

Aricept added $482m to Pfizer's top line in 2008, and the drug accounted for 38 per cent of Eisai's sales for the nine months ending December 31, 2008.

11th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics